AVTX
Companies
NASDAQ
Avalo Therapeutics, Inc.
Health Care
$4.90
-$2.54 (-34.12%)
Price Chart
Overview
About AVTX
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Market Cap
$10.6M
Volume
329.1K
Avg. Volume
417.5K
P/E Ratio
-1.225532
Dividend Yield
0.00%
Employees
25.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.25
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, AVTX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025